Q4 Earnings Forecast for NAMS Issued By Leerink Partnrs

NewAmsterdam Pharma (NASDAQ:NAMS) – Research analysts at Leerink Partnrs issued their Q4 2025 earnings per share (EPS) estimates for NewAmsterdam Pharma in a report issued on Tuesday, December 17th. Leerink Partnrs analyst R. Ruiz anticipates that the company will post earnings of ($0.35) per share for the quarter. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for NewAmsterdam Pharma’s FY2028 earnings at $0.42 EPS.

NAMS has been the topic of several other research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Needham & Company LLC restated a “buy” rating and set a $36.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Scotiabank upped their price objective on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a report on Wednesday, December 11th. Finally, Piper Sandler restated an “overweight” rating and set a $37.00 target price on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Six research analysts have rated the stock with a buy rating, According to MarketBeat, NewAmsterdam Pharma presently has a consensus rating of “Buy” and a consensus price target of $36.20.

NewAmsterdam Pharma Stock Down 1.1 %

Shares of NewAmsterdam Pharma stock traded down $0.29 during trading on Thursday, hitting $25.60. 233,950 shares of the stock traded hands, compared to its average volume of 373,830. The company has a fifty day moving average price of $21.01 and a two-hundred day moving average price of $18.86. NewAmsterdam Pharma has a twelve month low of $10.29 and a twelve month high of $27.29.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Banque Cantonale Vaudoise bought a new stake in NewAmsterdam Pharma in the 2nd quarter valued at $38,000. Quarry LP increased its stake in NewAmsterdam Pharma by 2,469.2% in the third quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after acquiring an additional 6,247 shares during the period. Barclays PLC raised its position in NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after purchasing an additional 7,199 shares in the last quarter. Bellevue Group AG bought a new position in NewAmsterdam Pharma during the third quarter worth about $128,000. Finally, XTX Topco Ltd bought a new stake in shares of NewAmsterdam Pharma in the 3rd quarter valued at approximately $187,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at NewAmsterdam Pharma

In related news, major shareholder Nap B.V. Forgrowth sold 166,011 shares of the stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $25.39, for a total value of $4,215,019.29. Following the completion of the sale, the insider now owns 11,150,461 shares in the company, valued at approximately $283,110,204.79. This trade represents a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Louise Frederika Kooij sold 45,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total value of $707,400.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 252,814 shares of company stock worth $5,970,327. 19.50% of the stock is owned by insiders.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.